Q2 2026 saw robust 14% growth in the portfolio, driving a 5% revenue increase to $13B and prompting raised full-year guidance. Key products like ELIQUIS, REBLOZYL, and CAMZYOS posted strong gains, while pivotal pipeline readouts and regulatory milestones are expected by year-end.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.